Takeda押注6亿美元与Insilico合作自动化早期药物发现
takeda与insilico medicine签署了价值6亿美元的协议，以利用其pharma.ai平台进行靶点发现。这表明制药巨头正开始将风险较高的早期研发外包给ai专家。
takeda entered a strategic collaboration with insilico medicine, potentially worth $600m, to deploy ai in identifying new drug targets and small molecule generation. the agreement leverages insilico's pharma.ai suite, specifically its generative biology and chemistry tools, to de-risk takeda's discovery pipeline. the partnership highlights a trend where large pharmaceutical firms outsource the most speculative part of r&d to specialized ai vendors rather than building internal tech. successful execution here could force competitors to abandon internal platform development in favor of similar outsourcing models.